Policy paper

Methylphenidate-based novel psychoactive substances: temporary class drug order recommendations

Recommendations for a temporary class drug order on a number of methylphenidate-based novel psychoactive substances.

Documents

Scheduling advice for methylphenidate-related NPS

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

ACMD position on methylphenidate-based NPS: February 2016

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Further advice on methylphenidate-related NPS: March 2017

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

These documents outline recommendations from the Advisory Council on the Misuse of Drugs (ACMD) on controlling a number of methylphenidate-based novel psychoactive substances (NPS) under a temporary class drug order.

You can also download a follow-up recommendation from the ACMD from February 2016 which advises on an extension of a temporary class drug order for methylphenidate-based NPS.

Published 8 April 2015
Last updated 23 March 2017 + full page history
  1. Letter of 23 March, detailing final scheduling advice, published.
  2. Published further advice on methylphenidate-related NPS.
  3. Follow up recommendation from the ACMD on methylphenidate-based NPS published.
  4. Addendum published.
  5. First published.